奥氮平联合氨磺必利治疗精神分裂症顽固性幻听的临床研究

摘要

Objective To investigate the effect of olanzapine combined with amisulpride treatment on refractory auditory hallucination in schizophrenia patients. Methods 140 patients with schizophrenia in our hospital from April 2013 to May 2014 were randomly divided into study group (n=70) and control group (n=70). The control group was given olanzapine ,and the study group received therapy of olanzapine combined with amisulpride for 8‐week treatment. The clinical efficacy before and af‐ter 4‐and 8‐week treatment and adverse events at 8‐week treatment were compared in two groups.Results The clinical effec‐tive rate was 87.14% in study group and 64.29% in control group ,with a significant difference. The scores of PNASS ,AHRS and CGI were significantly lower in both groups after treatment ,and the difference had statistically significance compared study group with control group after 4‐and 8‐week treatment(P<0.05);Adverse reactions occurred in 13 cases(18.57% ) in study group and 46 cases(65.71% ) in control group ,with a significant difference.Conclusion Clinical effect of olanzapine combined amisulpride for refractory auditory hallucinations in schizophrenia is significant ,with a good safety and few adverse reactions. It's worthy of clinical applitcation.%目的：探讨奥氮平联合氨磺必利治疗精神分裂症顽固性幻听的临床疗效。方法选择2013‐04—2014‐05来院就诊的精神分裂症患者140例，随机分为治疗组（n＝70）和对照组（n＝70）。对照组采用奥氮平治疗，治疗组采用奥氮平联合氨磺必利治疗，治疗8周，观察比较2组在治疗前和治疗第4、8周末时临床疗效及不良反应情况。结果治疗组临床有效率（87.14％）与对照组（64.29％）相比差异有统计学意义；2组在给药后PNASS、AHRS和CGI评分均显著降低，治疗组在治疗4周和8周时与对照组相比，差异具有统计学意义（ P＜0.05）；治疗组发生不良反应13例（18.57％），对照组46例（65.71％），差异具有统计学意义（P＜0.05）。结论奥氮平联合氨磺必利治疗精神分裂症的临床疗效显著，安全可靠，不良反应少，值得临床推广应用。